Translational Medical Research Commons^™

Underreporting Of Patient-Reported Outcomes In Myeloproliferative Neoplasms Clinical Trials, Anthony Messina, Quentin O'Brien

Clinical Research and Leadership Faculty Posters and Presentations

Introduction

Improvements in overall survival (OS) and quality of life (QoL) are clinically relevant outcomes that should guide clinical decision-making. Patients with MPNs can live with their disease for a long period of time, which increases the importance of understanding the impact of treatment in regards to a patients’ Health-Related QoL. Therefore, including PROs in clinical trials has become paramount in facilitating informed treatment decisions made by health care providers and patients. Furthermore, the FDA encourages the implementation of patient-centric measures in clinical trials.

Objective

We aimed to evaluate the frequency at which PRO measures are utilized as study endpoints …